NEW YORK, NY / ACCESSWIRE / May 8, 2018 / A strong performance by the energy sector lifted U.S. markets higher for the second consecutive session Monday as oil prices topped $70 a barrel. Investor attention will now shift to President Trump’s decision on the Iran nuclear accord on Tuesday at 2:00 p.m. The Dow Jones Industrial Average gained 0.39 percent to close at 24,357.32, while the S&P 500 Index rose 0.35 percent to close at 2,672.63. The Nasdaq Composite Index jumped 0.77 percent to close at 7,265.21.
“We’re waiting on more clarity about the Iran deal. If Trump pulls out, which other leaders have urged him not to do, then supply will be cut, which will have the same impact as rising demand in terms of driving up prices. But even beyond that, we’re entering the summer driving season and the energy sector has been down for so long that it looks poised for a rebound,” said Mark Martiak, senior wealth strategist at Premier Wealth/First Allied.
RDI Initiates Coverage on:
Brainstorm Cell Therapeutics Inc.
Cel-Sci's stock jumped 17.09% Monday, to close the day at $2.74. The stock recorded a trading volume of 388,306 shares, which was above its three months average volume of 243,062 shares. In the last year, Cel-Sci's shares have traded in a range of 1.75 - 2.74. The share price has gained 56.57% from its 52 week low. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $2.11 is at its 200-day moving average of $2.11. Shares of Cel-Sci have gained roughly 51.38 percent year-to-date.
Access RDI's Cel-Sci Corporation Research Report at:
On Monday, shares of Brainstorm Cell Therapeutics recorded a trading volume of 695,137 shares, which was above the three months average volume of 57,373 shares. The stock ended the day 7.85% higher at 3.71. The share price has gained 28.82% from its 52 week low with a 52 week trading range of 2.88 - 5.18. The company's shares are currently trading above their 200-day moving average. The stock's 50-day moving average of $3.32 is below its 200-day moving average of $3.58. Shares of Brainstorm Cell Therapeutics have gained roughly 11.08 percent in the past month and are down 5.36 percent year-to-date.
Access RDI's Brainstorm Cell Therapeutics Inc. Research Report at:
Our Actionable Research on Cel-Sci Corporation ( NYSE AMERICAN: CVM) and Brainstorm Cell Therapeutics Inc. (BCLI) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute